ReviewCurrent opinion in immunology2020
A key control point in the T cell response to chronic infection and neoplasia: FOXO1.
Review in Current opinion in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Host-virus miRNA crosstalk in ebola virus disease.Folia microbiologica · 2026Review
- Foxo1 regulates intestinal tissue-resident memory CD8 T cell biology in an anatomic compartment- and context-specific manner.Science immunology · 2025Article
- HScience advances · 2024Article
- Metabolic landscape of the healthy pancreas and pancreatic tumor microenvironment.JCI insight · 2024Article
- Identification and Potential Roles of Human MicroRNAs in Ebola Virus Infection and Disease Pathogenesis.Genes · 2024Article
- Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.Theranostics · 2024Article
- FOXO1 is a master regulator of CAR T memory programming.Research square · 2023Article
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
- Recent insights into the role of Akt in CD4 T-cell activation and differentiation: alternative splicing and beyond.Immunometabolism (Cobham, Surrey) · 2023Review
- Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
T cells able to control neoplasia or chronic infections display a signature gene expression profile similar or identical to that of central memory T cells. These cells have qualities of self-renewal and a plasticity that allow them to repeatedly undergo activation (growth, proliferation, and differentiation), followed by quiescence. It is these qualities that define the ability of T cells to establish an equilibrium with chronic infectious agents, and also preserve the ability of T cells to be re-activated (by checkpoint therapy) in response to malignant cancers. Here we describe distinctions between the forms of inhibition mediated by tumors and persistent viruses, we review the properties of T cells associated with long-term immunity, and we identify the transcription factor, FOXO1, as the control point for a program of gene expression that allows CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.